Tenofovir vs Entecavir After Resection in HBV-Related HCC: Survival Insights

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatocellular carcinoma (HCC) worldwide, particularly in regions with high HBV prevalence. Curative liver resection is a primary therapeutic strategy for eligible patients with HBV-related HCC, but recurrence rates remain substantial. Antiviral therapy targeting HBV replication—especially using nucleos(t)ide analogues such as entecavir (BMS200475) and tenofovir disoproxil—has become an integral component of post-resection management, aiming to suppress viral load, reduce recurrence, and improve overall survival (OS). However, the comparative effectiveness of these two first-line agents for patients following curative resection had not been conclusively established, motivating the present investigation.

Key Innovation from the Reference Study

The pivotal innovation of the study by Li et al. (JAMA Network Open, 2023) is its robust, propensity score–matched comparison of long-term outcomes between tenofovir disoproxil and entecavir in a real-world, high-volume tertiary setting. By enrolling 4451 patients and closely matching 989 patients per treatment group, the study overcomes many confounding variables that have limited prior retrospective analyses. Importantly, it provides quantitative estimates of OS and recurrence-free survival (RFS) at 1, 3, and 5 years, directly informing clinical decision-making for chronic hepatitis B infection therapy in patients with HCC after surgery.

Methods and Experimental Design Insights

This retrospective cohort study was conducted at the Eastern Hepatobiliary Surgery Hospital in Shanghai, China, encompassing patients with confirmed HBV-related HCC who underwent curative-intent liver resection between January 2015 and December 2018. The primary exposures compared were receipt of tenofovir disoproxil versus entecavir as postoperative antiviral therapy. Propensity score matching at a 1:1 ratio ensured that baseline demographic and clinical features, including age, sex, tumor stage, liver function, and intraoperative variables, were well balanced between groups. Median follow-up was 51 months, enabling robust assessment of long-term outcomes. The primary endpoints were RFS and OS rates, with hazard ratios and restricted mean survival time differences calculated to quantify group differences.

Protocol Parameters

• Patient inclusion: Chronic HBV infection with HCC, curative liver resection, no prior antiviral resistance.
• Antiviral regimen: Initiate tenofovir disoproxil or entecavir postoperatively; dosing per standard clinical guidelines (entecavir 0.5–1 mg/day; see product information for in vitro and clinical dosing reference).
• Follow-up: Regular clinical, laboratory, and imaging assessments to monitor recurrence and survival; median 51 months (range 3–91 months).
• Endpoints: Recurrence-free survival (RFS) and overall survival (OS) at 1, 3, and 5 years post-resection.

Core Findings and Why They Matter

Among the matched cohorts, the study reported that at 5 years post-resection, the OS rate was 54.2% for the entecavir group and 64.0% for the tenofovir group. Similarly, the 5-year RFS was 43.3% with entecavir and 51.4% with tenofovir. Both OS and RFS were statistically higher in the tenofovir group, with hazard ratios of 0.82 (OS) and 0.81 (RFS) in favor of tenofovir (reference study). Though the absolute differences at early time points (1 and 3 years) were modest, cumulative benefit at 5 years was clinically meaningful. These results suggest that in the context of postoperative management for HBV-related HCC, tenofovir may offer superior long-term protection against recurrence and mortality compared to entecavir, supporting its consideration as a preferred agent for chronic hepatitis B virus replication inhibition in this scenario.

It is notable that both drugs remain highly potent HBV DNA polymerase inhibitors, and the overall survival rates in both groups reflect the value of antiviral therapy as a whole in this high-risk population. The findings are particularly relevant for patients with decompensated liver disease or those at elevated risk of recurrence, as they reinforce the centrality of nucleos(t)ide analogue therapy for durable disease control.

Comparison with Existing Internal Articles

Several recent internal resources provide detailed mechanistic and workflow perspectives on entecavir's role in chronic HBV infection therapy. For example, this article dissects how entecavir, as a selective hepatitis B virus reverse transcriptase inhibitor, achieves precision in viral suppression and highlights its low resistance profile. Similarly, another review explores entecavir's clinical and translational positioning, especially for lamivudine-resistant HBV treatment and for patients with decompensated liver disease. These resources emphasize entecavir's strengths: high antiviral potency, favorable safety, and established efficacy even in complex patient cohorts.

The present cohort study contextualizes these mechanistic and clinical insights by benchmarking entecavir directly against tenofovir in a rigorous, real-world postoperative setting. While internal articles underscore entecavir's reliability and broad applicability—including in resistant or advanced disease—this new evidence suggests that, in the specific population of HBV-related HCC post-resection, tenofovir may provide incremental long-term benefit in recurrence and survival. This does not diminish entecavir's critical utility in chronic HBV management, especially given its proven track record in both naïve and lamivudine-resistant cases, as extensively reviewed in internal workflow guidance (see scenario-driven analysis).

Limitations and Transferability

Despite its strengths, the study is limited by its retrospective, single-center design and focus on an exclusively Chinese population, which may limit generalizability to other geographic or ethnic groups. While propensity score matching controls for many confounders, unmeasured or residual biases may persist. Additionally, the study does not address molecular mechanisms underlying the observed survival differences, nor does it evaluate the impact of antiviral resistance emergence during prolonged therapy. Importantly, both agents demonstrated high overall efficacy, and the choice between them should also consider individual patient factors, such as renal function, prior antiviral exposure, and access to monitoring. Transferability of these findings to patients with non-surgical management, or to those with multi-drug resistance, remains to be defined in future prospective trials.

Research Support Resources

For researchers aiming to replicate or extend these findings in preclinical or translational models, Entecavir (SKU BA1816) from APExBIO is available as a potent and selective HBV DNA polymerase inhibitor. This reagent is suitable for in vitro assessment of chronic hepatitis B virus replication inhibition, including assays evaluating lamivudine-resistant strains and workflow optimization in HBV research. See product specifications for dosing and compatibility. For additional mechanistic insights or experimental design strategies, refer to internal reviews linked above. Careful selection and validation of nucleos(t)ide analogues remain essential for advancing chronic hepatitis B research and improving outcomes in high-risk cohorts.